Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...

Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Oppenheimer reiterated its “Outperform” rating and a price target of $255.00 on the company’s shares. Biogen Inc. (NASDAQ:BIIB)’s commercial strategies are expected to enhance the uptake ...

Auditor/Auditors for Biogen Pharmachem Industries Ltd is/are Rishi Sekhri & Associates. In the main management, is chairman and Khushboo Khandelwal is the company secretary for Biogen Pharmachem ...

For Biogen, the technology could help with its ambitions to develop novel neurological disease candidates. The company placed big bets on its Alzheimer’s drug aducanumab which has so far ...

Telehealth company Talkiatry has partnered with Biogen to expand its support service for women who develop postpartum depression (PPD) in a move that could help drive uptake of the latter's new ...

After hours: February 7 at 7:59:46 PM EST ...